As Washington focuses on bolstering American industrial leadership and global competitiveness, one biopharmaceutical company is already writing the next chapter. Gilead Sciences is making a $32 billion investment in its American home base, reaffirming this location as the center that drives Gilead’s ability to develop and deliver critical medicines around the world.
This is about reinforcing America’s position as the global leader in pharmaceutical innovation, proving that breakthroughs can be discovered and delivered at home, and building where scientific excellence and American ingenuity shape medicine’s future.
A MODEL FOR LEADERSHIP
For too long, conversations about domestic manufacturing focused on what the U.S. is losing. Gilead’s investment tells a different story: what they’re expanding. The company’s R&D function is already 98% U.S.-based, demonstrating its belief that world-changing science begins at home. Gilead’s continued investment will allow the company to build the infrastructure and cultivate the workforce to unlock tomorrow’s cures. It will also solidify America as the center of biopharmaceutical innovation for generations.
The commitment is tangible. Through 2030, Gilead will create 800 direct jobs and support 2,200 additional positions, generating $43 billion in domestic economic impact. But these figures hint at the larger transformation: careers training the next generation of scientists, communities benefiting from sustained investment, and capabilities ensuring America leads during future health crises.
Read the article.